Finance

Lists
DNA:NYSE
Ginkgo Bioworks Holdings Inc
10,46 $
-1,88%
(-0,20) 1D
10,47 $
+0,10% (+0,010)
Pre-market
Closed: 28 қыр., 16:00:03 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNA...
Open
10,38 $
High
10,79 $
Low
10,10 $
Mkt. cap
673,00 млн
Avg. vol.
1,46 млн
Volume
4,42 мың
52-wk high
17,58 $
52-wk low
5,37 $
EPS
-5,00 $
Beta
1,76
Shares outstanding
55,38 млн
No. of employees
485
Open
10,38 $
High
10,79 $
Low
10,10 $
Mkt. cap
673,00 млн
Avg. vol.
1,46 млн
Volume
4,42 мың
52-wk high
17,58 $
52-wk low
5,37 $
EPS
-5,00 $
Beta
1,76
Shares outstanding
55,38 млн
No. of employees
485
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersБостон, Массачусетс, Америка Құрама Штаттары
Sector-
Websiteginkgo.bio
Analyst ratings
Based on 3 analysts giving stock ratings to DNA in the past 3 months
Sell
Buy
0
Hold
1
Sell
2
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for DNA in the last 3 months.
Highest
Current 10,46 $
9,00 $ (-13,96%)
Average
7,00 $ (-33,08%)
Lowest
5,00 $ (-52,20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mark Massaro
BTIG
Sell
Reiterated
5,00 $
-52,2%
09/04/2026
Jared Haase
William Blair
Sell
Maintained
-
-
08/13/2026
Brendan Smith
TD Cowen
Hold
Downgraded
9,00 $
-14%
08/07/2026
Matt Larew
William Blair
Sell
Reiterated
-
-
05/11/2026
Last report
2026 ж. 05 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,73 $ / -0,70 $
-4,66%miss
Revenue / Est. (USD)
20,16 млн / 48,93 млн
-58,81%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
38,84 млн
33,40 млн
19,47 млн
20,16 млн
Cost of goods sold
12,80 млн
7,30 млн
3,10 млн
1,72 млн
Cost of revenue
12,80 млн
7,30 млн
3,10 млн
1,72 млн
Research and development expenses
69,35 млн
50,13 млн
49,92 млн
46,21 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
44,95 млн
46,01 млн
37,83 млн
29,67 млн
Operating expense
114,31 млн
96,14 млн
87,75 млн
75,88 млн
Total operating expenses
127,11 млн
103,44 млн
90,85 млн
77,60 млн
Operating income
-88,27 млн
-70,05 млн
-71,37 млн
-57,44 млн
Other non operating income
-163,00 м.
821,00 м.
-388,00 м.
809,00 м.
EBT including unusual items
-80,75 млн
-81,39 млн
-76,14 млн
-57,19 млн
EBT excluding unusual items
-82,69 млн
-62,01 млн
-68,17 млн
-58,07 млн
Income tax expense
1,00 мың
-643,00 м.
-80,00 мың
128,00 м.
Effective tax rate
-
0,79%
0,10%
-0,22%
Other operating expenses
-
-
-
-
Net income
-80,76 млн
-80,75 млн
-82,59 млн
-46,71 млн
Net profit margin
-207,93%
-241,80%
-424,09%
-231,74%
Earnings per share
-
-0,77
-
-0,73
Interest and investment income
5,74 млн
7,21 млн
3,60 млн
3,23 млн
Interest expense
-
-
-
-
Net interest expenses
5,74 млн
7,21 млн
3,60 млн
3,23 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-88,10 млн
-61,08 млн
-62,78 млн
-49,23 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары